): It is clear that estrogen exposure plays an important role in the etiology of breast cancer. However, in addition to the well-characterized and well-accepted role of estrogen receptor-dependent events in the pathophysiology of breast cancer, a parallel and complementary hypothesis has developed in support of direct estrogen-mediated genotoxicity after the """"""""metabolic activation"""""""" of estrogens to form catecholestrogens (CEs). Many of the enzymes which are involved in estrogen and CE formation, in their metabolic activation to form genotoxins and in their enzymatic inactivation to prevent genotoxicity display common, functionally significant genetic polymorphisms. Therefore, one possible mechanism for the effects of """"""""predisposing genes"""""""" in the pathophysiology of breast cancer would result from the effects of common genetic polymorphisms involving enzymes that catalyze the activation of estrogens and CEs to form genotoxins or the enzymatic inactivation of those genotoxins. We propose to take advantage of the unusual resource represented by the 426 families that we have identified through probands diagnosed with breast cancer to systematically test the hypothesis that common genetic polymorphisms for enzymes that catalyze pathways of estrogen and CE formation, CE metabolic activation to form genotoxins or the metabolic inactivation of those genotoxins might represent """"""""predisposing"""""""" genetic risk factors that can partially explain the familial clustering of breast cancer beyond mutations within the BRCA1 and BRCA2 genes. Specifically, allele frequencies for common genetic polymorphisms of enzymes, predominantly cytochromes P450, that are involved in pathways of estrogen formation and metabolic activation as well as enzymes involved in estrogen and CE metabolism and inactivation (e.g., methylation, sulfation and glutathione conjugation) will be determined in 434 breast cancer cases and 868 control subjects to determine whether genetic polymorphisms for enzymes that catalyze estrogen metabolic bioactivation and/or inactivation might represent inherited risk factors for the occurrence of this common neoplastic disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA082267-02
Application #
6494759
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2001-08-29
Project End
2002-06-30
Budget Start
Budget End
Support Year
2
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Darabi, Hatef; McCue, Karen; Beesley, Jonathan et al. (2015) Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. Am J Hum Genet 97:22-34
Kelemen, Linda E; Atkinson, Elizabeth J; de Andrade, Mariza et al. (2010) Linkage analysis of obesity phenotypes in pre- and post-menopausal women from a United States mid-western population. BMC Med Genet 11:156
Manduca, Armando; Carston, Michael J; Heine, John J et al. (2009) Texture features from mammographic images and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 18:837-45
Sinicrope, Pamela S; Patten, Christi A; Clark, Lara P et al. (2009) Adult daughters' reports of breast cancer risk reduction and early detection advice received from their mothers: an exploratory study. Psychooncology 18:169-78
Kelemen, Linda E; Pankratz, V Shane; Sellers, Thomas A et al. (2008) Age-specific trends in mammographic density: the Minnesota Breast Cancer Family Study. Am J Epidemiol 167:1027-36
Myers, Cynthia D; Jacobsen, Paul B; Huang, Yifan et al. (2008) Familial and perceived risk of breast cancer in relation to use of complementary medicine. Cancer Epidemiol Biomarkers Prev 17:1527-34
Cox, Angela; Dunning, Alison M; Garcia-Closas, Montserrat et al. (2007) A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 39:352-8
Vachon, Celine M; Sellers, Thomas A; Carlson, Erin E et al. (2007) Strong evidence of a genetic determinant for mammographic density, a major risk factor for breast cancer. Cancer Res 67:8412-8
Olson, Janet E; Ma, Cynthia X; Pelleymounter, Linda L et al. (2007) A comprehensive examination of CYP19 variation and breast density. Cancer Epidemiol Biomarkers Prev 16:623-5
Olson, Janet E; Ingle, James N; Ma, Cynthia X et al. (2007) A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches. Breast Cancer Res Treat 102:237-47

Showing the most recent 10 out of 27 publications